Synthetic Cannabinoids in Russia: A Group-Belonging Rehabilitation Model from Tomsk
- Sample of 311 young men dependent on synthetic cannabinoids ("spice"-class designer drugs): 169 with specific and persistent personality disorders, 142 with paranoid schizophrenia — recruited at Mental Health Research Institute, Tomsk National Research Medical Center.
- Standard rehabilitation in this comorbid population yielded short, brittle remissions; clinicians documented serial relapse driven by the patient's need to remain inside an addictive peer community.
- The Tomsk team designed a rehabilitation programme that does not try to dissolve the group bond — instead it substitutes the addictive community with a structured, socially acceptable group identity, monitored with ICD-10, CGI, GAF and SANS.
- Across follow-up the substituted-community model improved remission length and quality, reduced relapse frequency, and improved global functioning compared with the patients' previous treatment courses.
Synthetic cannabinoids — the SC-receptor agonists sold under "spice", "JWH", "K2" street labels — produce a faster, more dysphoric and more psychotogenic course than herbal cannabis, and in CIS clinical reality they cluster with paranoid schizophrenia and persistent personality disorders. The Tomsk paper is not a glamorous RCT. It is a 311-patient observational programme from a regional psychiatric service, which is exactly the kind of source we should be reading: it describes what addiction medicine actually looks like east of Moscow, where relapse is socialised inside a tight peer group long before any pharmacology or CBT can take hold.
What the Tomsk team did differently
The conventional move in dual-diagnosis SC dependence is to extract the patient from the using community, then build pro-social skills from zero. Bokhan and colleagues report that this fails for a large subgroup, especially men with paranoid SZ, because the group is doing important psychic work — it organises identity, it manages negative symptoms, it externalises affect that the patient cannot self-regulate. Take it away and you take away the only structure the patient has.
So the Tomsk programme inverted the logic. Instead of removing the addictive group, it offers a substitute group: a structured, supervised therapeutic community matched to the patient's ethno-territorial profile (Siberian regional context, peer composition, local norms), with a programme that uses ICD-10 diagnostic anchors, CGI and GAF for global function, and SANS for negative symptoms in the SZ subsample. Outcomes are framed as longer and "higher-quality" remissions and reduced relapse — descriptive rather than effect-size language, which is honest given the design.
For your practice
If you treat SC-dependent patients with comorbid SZ or persistent PD — and in CIS clinical loads this is now a routine combination — the practical takeaway is that the group is not just a risk factor, it is a treatment lever. Concretely: when you plan rehabilitation for a young man with paranoid SZ and synthetic-cannabinoid use, do not assume that isolating him from his peer environment is therapeutic. Plan a same-shape replacement community before discharge, not after the first relapse. Use SANS at intake and at 3-month checkpoints to track whether the substitute group is doing what the using group was doing — affect regulation, identity scaffolding, daily structure. If those negative-symptom scores are not moving, the new community is decorative.
In synthetic-cannabinoid dependence with paranoid schizophrenia, the addictive peer group is doing psychic work the patient cannot do alone — rehabilitation has to replace that work, not merely remove the group.
Single-region observational design without randomisation or an active comparator; outcome reporting is descriptive rather than quantitative effect sizes; male-only sample limits generalisability to women with SC dependence.